Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an MO cutaneous melanoma, full report;Recommandations pour la pratique clinique: Standards, Options et Recommandations 2005 pour la prise en charge des patients adultes atteints d'un mélanome cutané MO, rapport intégral

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 12 C2, 2005, Pages

  Negrier S ^a   Saiag, P ^a   Guillot, B ^a   Verola, O ^a   Avril, M F ^a   Bailly, C ^a   Cupissol, D ^a   Dalac, S ^a   Danino, A ^a   Dreno, B ^a   Grob, J J ^a   Leccia, M T ^a   Renaud Vilmer, C ^a   Bosquet, L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CANCER VACCINE; DACARBAZINE; GAMMA INTERFERON; GANGLIOSIDE GM2 HEMOCYANIN CONJUGATE; INTERLEUKIN 2; MEGESTROL ACETATE; MELACINE; MELANOMA VACCINE; MELPHALAN; PLACEBO; QS 21; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; ECHOGRAPHY; EDEMA; FATIGUE; FEVER; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION SITE ERYTHEMA; INJECTION SITE ULCER; LYMPH NODE METASTASIS; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALAISE; MEDICAL LITERATURE; MEDICAL RESEARCH; MELANOMA; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROGNOSIS; RADIATION INJURY; REVIEW; SCINTIGRAPHY; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL DISORDER; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CASE MANAGEMENT; DECISION TREE; EVIDENCE BASED MEDICINE; FOLLOW UP; IMMUNOTHERAPY; LYMPHADENECTOMY; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASE MANAGEMENT; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DECISION TREES; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33646154893     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (243)

1. Fervers B, Bonichon F, Demard F, Heron JF, Mathoulin S, Philip T, et al. Méthodologie de développement des Standards, Options et Recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995;82:761-7.
2. Fervers B, Hardy J, Blanc-Vincent MP, Theobald S, Bataillard A, Farsi F, et al. SOR: project methodology. Br J Cancer 2001;84:8-16.
3. Negrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Doré JF, et al. Standards, Options et Recommandations : Mélanome cutané. Paris: John Libbey EUROTEXT, 1998. Standards, Options & Recommandations, vol 6.
4. Negrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Dore JF, et al. Standards, Options et Recommandations pour la prise en charge des patients atteints de mélanome cutané. Bull Cancer 2000;87:173-82.
5. Negrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Dore JF, et al. Cutaneous melanoma. Br J Cancer 2001;84:81-5.
6. Suivi des patients opérés d'un mélanome de stade I. Conférence de consensus. Paris: Agence nationale pour le développement de l'évaluation médicale (ANDEM), 1995.
7. Suivi des patients opérés d'un mélanome de stade I. Conférence de consensus. Ann Dermatol Venerol 1995;122(5).
8. SIGN, (Scottish Intercollegiate Guidelines Network). Cutaneous melanoma [online]. 2003. Available: URL: http://www.sign.ac.uk/guidelines/fulltext/72/ index.html.
9. NHMRC, (National Health and Medical reserach Council). The managment of cutaneous melanoma [online]. 1999. Available: URL: http://www.nhmrc.gov.au/ publications/synopses/cp68syn.htm.
10. Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, et al. U.K. guidelines for the management of cutaneous melanoma [Comment in: Br J Dermatol. 2002 Oct;147(4):832-4; author reply 834-5; Comment in: Br J Dermatol. 2002 Oct;147(4):834;Comment in: Br J Dermatol. 2002 Oct;147(4):835-6; author reply 836-7;Comment in: Br J Dermatol. 2002 Oct;147(4):837-8; author reply 838;Comment in: Br J Dermatol. 2003 May;148(5):1081-2; author reply 1082]. Br J Dermatol 2002;146:7-17.
11. AADA, (American academy of dermatology association). Guidelines for care for primary cutaneous melanoma [online]. 2001. Available: URL: http://www.aadassociation.org/Guidelines/CutaneousMel.html.
12. CCOPGI, (Cancer Care Ontario Practice Guidelines Initiative). Systemic adjuvant therapy for patients at high risk for recurrent melanoma. Practice Guideline Report No 8-1 [online]. 2002. Available: URL: http://www.cancercare. on.ca/index_practiceGuidelinesandEvidencesummaries.htm#list.
13. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005;210:39-44.
14. Kroon BB, Bergman W, Coebergh JW, Ruiter DJ. Consensus on the management of malignant melanoma of the skin in The Netherlands. Dutch Melanoma Working Party. Melanoma Res 1999;9:207-12.
15. Lawrence WD. ADASP recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. Virchows Arch 2001;439:601-3.
16. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000;89:236-41.
17. AHRQ, Agency for Healthcare Research and Quality. Screening for Skin Cancer. File Inventory, Systematic Evidence Review Number 2 [online]. AHRQ Publication 2001. Available: URL: http://www.ahrq.gov/clinic/prev/skncainv.htm.
18. Union internationale contre le cancer, ed. TNM classification of malignant melanoma. 2nd ed. Geneva: UICC, 1978.
19. Goldsmith HS. Melanoma: an overview. CA Cancer J Clin 1979;29:194-215.
20. Mastrangelo MJ, Rosenberg SA, Becker AR. Cutaneous melanoma. In: DeVita TV, Hellmann, S, Rosenberg, SA, eds. Principles and pratice of oncology. Philadelphia: Lippincott Company, 1993;1124-70.
21. American joint committee on cancer, ed. Manual for staging of cancer. 2nd ed. Philadelphia: Lippincott Company, 1983.
22. Spiessl B, Beahrs OH, Hermanl P, Hutter RV, Scheibe O, Sobin LH, eds. TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumors. 3rd ed. Berlin: Springer-Verlag, 1992.
23. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system [Comment in: J Clin Oncol. 1997;15(:3026]. J Clin Oncol 1997;15:1039-51.
24. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. Ann Surg Oncol 2001;8:101-8.
25. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
26. Greene FL, Page D.L., et al. AJCC cancer staging manuel. 6th ed. New York: Springer-Verlag, 2002.
27. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-49.
28. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438-41.
29. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial [Comment in: Ann Surg. 1993;218:702]. Ann Surg 1993;218:262-7.
30. Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0. Cancer 1996;77:1809-14.
31. Diagnosis and treatment of early melanoma. NIH consensus development conference. Consensus statement 1992;10:1-25.
32. ANDEM, ed. Tumeurs cutanées. Service des références médicales. Agence nationale pour le développement de l'évaluation en santé, 1994.
33. Lens MB, Dawes M, Goodacre T, Bishop JA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Archives of Surgery 2002;137:1101-5.
34. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003;46:419-26.
35. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm [Erratum in: N Engl J Med 1991 Jul 25;325(4):292]. N Engl J Med 1988;318:1159-62.
36. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996;3:446-52.
37. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000;89:1495-501.
38. Banzet P, Thomas A, Vuillemin E, et al. Wide versus narrow surgical excision in thin (< 2mm) stage I primary cutaneous melanoma: long term results of a French multicentric prospective randomized trial on 319 patients [abstract]. Proc Am Assoc Clin Oncol 1993;12:387.
39. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm) for lesions measuring less than 2. Cancer 2003;97:1941-6.
40. Thomas JM, Newton-Bishop J, A'Hern R, Coombes G, Timmons M, Evans J, et al. Excision margins in high-risk malignant melanoma [Comment in: N Engl J Med. 2004 Feb 19;350(8):823-5]. N Engl J Med 2004;350:757-66.
41. Cohen LM, McCall MW, Zax RH, Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. Dermatologic Surgery 1998;24:673-7.
42. Malhotra R, Chen C, Huilgol SC, Hill DC, Selva D, Malhotra R, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology 2003;110:2011-8.
43. Huilgol SC, Selva D, Chen C, Hill DC, James CL, Gramp A, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol 2004;140:1087-92.
44. Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up [Comment in: Arch Dermatol. 2004 May;140(5):607-8]. Arch Dermatol 2004;140:552-8.
45. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
46. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-91.
47. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann of Surg Oncol 1999;6:442-9.
48. Lenisa L, Santinami M, Belli F, Clemente C, Mascheroni L, Patuzzo R, et al. Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients. J Exp Clin Cancer Res 1999;18:69-74.
49. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999;230:453-63.
50. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000;87:484-9.
51. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? [comment]. Ann of Surg Oncol 2001;8:192-7.
52. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann of Surg Oncol 2000;7:469-74.
53. Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, van Diest PJ, Pijpers R, Ferwerda CC, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer 2001;91:2401-8.
54. Carcoforo P, Soliani G, Bergossi L, Basaglia E, Virgili AR, Pagani W, et al. Reliability and accuracy of sentinel node biopsy in cutaneous malignant melanoma. Tumori 2002;88:S14-S16.
55. Chao C, Wong SL, Ross MI, Reintgen DS, Noyes RD, Cerrito PB, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002;184:520-4.
56. Doting MH, Hoekstra HJ, Plukker JT, Piers DA, Jager PL, Tiebosch AT, et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol 2002;28: 673-8.
57. Stojadinovic A, Allen PJ, Clary BM, Busam KJ, Coit DG. Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg 2002;235:92-8.
58. Chao C, Wong SL, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol 2003;10:21-6.
59. Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003;200:314-9.
60. Vuylsteke RJ, van Leeuwen PA, Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003;21:1057-65.
61. Wrightson WR, Wong SL, Edwards MJ, Chao C, Reintgen DS, Ross MI, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003;10 :676-80.
62. Statius Muller MG, Borgstein PJ, Pijpers R, van Leeuwen PA, van Diest PJ, Gupta A, et al. Reliability of the sentinel node procedure in melanoma patients: analysis of failures after long-term follow-up. Ann of Surg Oncol 2000;7:461-8.
63. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410-5.
64. Blaheta HJ, Ellwanger U, Schittek B, Sotlar K, Maczey E, Breuninger H, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;114:637-42.
65. Haigh PI, Lucci A, Turner RR, Bostick PJ, Krasne DL, Stern SL, et al. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer 2001;92:535-41.
66. Palmieri G, Ascierto PA, Cossu A, Mozzillo N, Motti ML, Satriano SM, et al. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. J Clin Oncol 2001;19:1437-43.
67. Kuo CT, Hoon DS, Takeuchi H, Turner R, Wang HJ, Morton DL, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes [Comment in: J Clin Oncol. 2003 Oct 1;21(19):3550-1]. J Clin Oncol 2003;21:3566-72.
68. Ribuffo D, Gradilone A, Vonella M, Chiummariello S, Cigna E, Haliassos N, et al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma [Comment in: Ann Surg Oncol. 2003 May;10(4):336-7.]. Ann Surg Oncol 2003;10:396-402.
69. Rimoldi D, Lemoine R, Kurt AM, Salvi S, Berset M, Matter M, et al. Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods. Melanoma Res 2003;13:511-20.
70. Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, Flotte TJ, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999;134:381-7.
71. Blumenthal R, Banic A, Brand CU, Ris HB, Lardinois D. Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma. Swiss Surg 2002;8:209-14.
72. Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL. Prognostic implications of thick (> OR = 4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann of Surg Oncol 2002;9:754-61.
73. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003;21:1326-31.
74. Fincher TR, McCarty TM, Fisher TL, Preskitt JT, Lieberman ZH, Stephens JF, et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg 2003;186:675-81.
75. Liszkay G, Peley G, Sinkovics I, Peter I, Orosz Z, Fejos Z, et al. Clinical significance of sentinel lymph node involvement in malignant melanoma. Pathol Oncol Res 2003;9:184-7.
76. Morton DL, Thompson JF, Cochran AJ, Essner R, Elashoff R, Multicenter selective lymphadenectomy trial group. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma. American society of clinical oncology; 2005. (abstr 7500).
77. Glass LF, Fenske NA, Messina JL, Cruse CW, Rapaport DP, Berman C, et al. The role of selective lymphadenectomy in the management of patients with malignant melanoma. Dermatol Surg 1995;21:979-83.
78. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
79. Dewar DJ, Newell B, Green MA, Topping AP, Powell BW, Cook MG. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 2004;22:3345-9.
80. CCOPGI, (Cancer Care Ontario Practice Guidelines Initiative). Systemic adjuvant therapy for patients at high risk for recurrent melanoma. [online]. 1997. Available: URL: http://www.cancercare.on.ca/ index_practiceGuidelinesandEvidencesummaries.htm#list.
81. Rumke P, Van Everdingehn JE. Consensus on the managment of melanoma of the skin in the Netherlands. Dutch Melanoma Workin Party. Eur J Cancer 1992;28:600-4.
82. Melanoma (cutaneous) PDQ information for health care professionnals, cancer net from the National cancer institute [online]. 1996. Available: URL: http://imsdd.meb.uni-bonn.de/cancernet/physicians.toc.htm.
83. Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G. Postsurgical adjuvant therapy for melanoma. Cancer 1997;79:2354-60.
84. Lens MB, Dawes M, Goodacre T, Newton-Bishop JA. Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surg 2002;137:458-61.
85. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme [Comment in: Lancet. 1998 Jun 20;351(9119):1884-5; Comment in: Lancet. 1998 Jun 20;351(9119):1884; author reply 1885; Comment in: Lancet. 1998 Jun 20;351(9119):1885]. Lancet 1998;351:793-6.
86. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-63.
87. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697-705.
88. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977;297:627-30.
89. Veronesi U, Adamus J, Bandiera DC, Brennhovd O, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
90. Baas PC, Schraffordt KH, Hoekstra HJ, van Bruggen JJ, van der Weele LT, Oldhoff J. Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity. Arch Surg 1992;127:281-6.
91. Beitsch P, Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. Am J Surg 1992;164:462-5.
92. Karakousis CP, Heiser MA, Moore RH. Lymphedema after groin dissection. Am J Surg 1983;145:205-8.
93. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial [Comment in: Ann Surg Oncol. 2000 Dec;7(10):789; Comment in: Ann Surg Oncol. 2000 Mar;7(2):75-6; Comment in: Ann Surg Oncol. 2000 Mar; 7(2):80-1]. Ann Surg Oncol 2000;7:87-97.
94. Meyskens FL, Jr., Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study [Comment in: J Natl Cancer Inst. 1996 Jul 3;88(13):926-7]. J Natl Cancer Inst 1995;87:1710-3.
95. Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390-402.
96. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818-25.
97. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29:241-52.
98. Pirard D, Heenen M, Melot C, Vereecken P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 2004;208:43-8.
99. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1. Lancet 1998;351:1905-10.
100. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866-9.
101. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425-9.
102. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma [Comment in: J Clin Oncol. 2004 Jan 1;22(1):11-4; Comment in: J Clin Oncol. 2004 Jan 1; 22(1):7-10.]. J Clin Oncol 2004;22:53-61.
103. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM, Jr., et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-83.
104. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 [Comment in: J Clin Oncol. 1996 Jan;14(1):1-3; Comment in: J Clin Oncol. 1996 Jun;14(6):1967-8; Comment in: J Clin Oncol. 1996 Jun; 14(6):1968-9;Comment in: J Clin Oncol. 2001 Feb 15;19(4):1226-8]. J Clin Oncol 1996;14:7-17.
105. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
106. Cascinelli N, Bufalino R, Morabito A, MacKie R. Results of adjuvant interferon study in WHO melanoma programme [Comment in: Lancet. 1994 Jun 11;343(8911):1498-9.]. Lancet 1994;343:913-4.
107. Cameron DA, Cornbleet MC, MacKie RM, Hunter JA, Gore M, Hancock B, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001;84:1146-9.
108. Hancock BW, Wheatley K, Harrison G, Gore M. Aim hig adjuvant interferon in melanoma (high risk), a United Kingdom co-ordinating commitee on cancer research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma [Abstract]. 2001. (abstr 1393).
109. Kleeberg UR, Broecker EB, Chartier C, et al. EORTC 18871 adjuvant trial in high risk melanoma patients IFN alpha vs IFN gamma vs iscador vs observation. Eur J Cancer 1999;35:264.
110. Eggermont AM, Kleeberg UR, Ruiter DJ, Suciu S. The European organization for research and treatment of cancer melanoma group trial experience with more than 2,000 patients evaluating adjuvant therapy treatment with low or intermediate doses of interferon-alpha 2b. In : Perry GM, ed. American Society of Clinical Oncology. Alexandria, VA, USA: Educational Book, 2001;88-93.
111. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19:1430-6.
112. Kokoschka EM, Trautinger F, Knobler RM, Pohl-Markl H, Micksche M. Long-term adjuvant therapy of high risk malignant melanoma with interferon alpha2b. J Invest Dermatol 1990;95:193S-7S.
113. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003;21:2883-8.
114. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913-6.
115. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 2004;100:1692-8.
116. Fisher RI, Terry WD, Hodes RJ, Rosenberg SA, Makuch R, Gordon HG, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 1981;61:1267-77.
117. Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181-90.
118. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-66.
119. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067-75.
120. Wallack MK, Sivanandham M, Ditaranto K, Shaw P, Balch CM, Urist MM, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997;226:198-206.
121. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69-77.
122. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine [Comment in: Clin Cancer Res. 2001 Jul;7(7):1837-8]. Clin Cancer Res 2001;7:1882-7.
123. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
124. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002;51:539-46.
125. Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dreno B, et al. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002;51:532-8.
126. Loutfi A, Shakr A, Jerry M, Hanley J, Shibata HR. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987;10:325-8.
127. Lejeune F, Macher E, Kleeberg UR, Rumke P, Prade M, Thomas D, et al. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after removal of a primary melanoma of the skin: a phase III adjuvant study (EORTC protocol 18761). Eur J Cancer 1988;24:S81-90.
128. Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group [Comment in: J Clin Oncol. 1991 May;9(5):716-7.]. J Clin Oncol 1991;9: 729-35.
129. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991;9:736-40.
130. Hill GJ, Moss SE, Golomb FM, Grage TB, Fletcher WS, Minton JP, et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040. Cancer 1981;47:2556-62.
131. Quirt IC, De Boer G, Kersey PA, Baker MA, Bodurtha AJ, Norwell ST. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 1983;128:929-33.
132. Creagan ET, Ingle JN, Schutt AJ, Schaid DJ. A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 1989;12:152-5.
133. Markovic S, Suman VJ, Dalton RJ, Woods JE, Fitzgibbons RJ, Jr., Wold LE, et al. Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. Am J Clin Oncol 2002;25: 552-6.
134. Ghussen F, Kruger I, Smalley RV, Groth W. Hyperthermic perfusion with chemotherapy for melanoma of the extremities [Comment in: World J Surg. 1990 Nov-Dec;14(6):845-6]. World J Surg 1989;13:598-602.
135. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906-12.
136. Creagan ET, Cupps RE, Ivins JC, Pritchard DJ, Sim FH, Soule EH, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 1978;42:2206-10.
137. Stevens G, Thompson JF, Firth I, O'Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000;88:88-94.
138. Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002;52:964-72.
139. Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003;97:1789-96.
140. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 2004;11:1079-84.
141. Burmeister BH, Smithers BM, Davis S, Spry N, Johnson C, Krawitz H, et al. Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ Journal of Surgery 2002;72:344-8.
142. DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer 2001;91:1520-4.
143. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985;13:756-60.
144. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988;166:497-502.
145. Rogers GS, Kopf AW, Rigel DS, Friedman RJ, Levenstein M, Bart RS. Hazard-rate analysis in state I malignant melanoma. Arch Dermatol 1986;122:999-1002.
146. Slingluff CL, Jr., Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992;70:1917-27.
147. Ho VC, Sober AJ. Therapy for cutaneous melanoma: an update. J Am Acad Dermatol 1990;22:159-76.
148. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of
149. McEwan L, Smith JG, Matthews JP. Late recurrence of localized cutaneous melanoma: its influence on follow-up policy. Plast Reconstr Surg 1990;86:527-34.
150. Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol 1994;20:175-8.
151. Thomas L. Quels sont les progrès espérés dans la surveillance et le traitement du mélanome de stade I ? Ann Dermatol Venereol 1995;122:378-88.
152. Fortier-Beaulieu M. Y-a-t-il des modalités de surveillance particulières imposées par certaines thérapeutiques du mélanome de stade I ? Ann Dermatol Venereol 1995;122:372-7.
153. Grange F. Mélanomes primitifs multiples et mélanome familial : évaluation du risque et mesures de dépistage. Comment apprécier le risque de développer un deuxième melanome chez le malade ? Dans sa famille ? Faut-il mettre en oeuvre des méthodes pour les dépister ? Lesquelles et pourquoi ? Ann Dermatol Venereol 1995;122:365-71.
154. Truchetet F, Chartier C. Quelles sont les méthodes de détection des récidives ? Quelle est leur valeur ? Faut-il les mettre en oeuvre ? Lesquelles et à quelle fréquence ? Ann Dermatol Venereol 1995;122:360-4.
155. Gautier MS. Devant un patient opéré d'un mélanome primitif isolé, quel est le risque évolutif de sa maladie ? Comment apprécier ce risque ? Ann Dermatol Venereol 1995;122:336-48.
156. Grob JJ. Méthodes de détection des récidives : lesquelles, à quelle fréquence et pendant combien de temps ? Ann Dermatol Venereol 1995;122:298-304.
157. Eggermont AM. Surveillance des malades atteints de mélanome de stade I après exérèse de la tumeur primitive. Ann Dermatol Venereol 1995;122:292-7.
158. Bonerandi JJ. Après exérèse d'un mélanome primitif faut-il faire un bilan initial ? Le point de vue d'un dermatologue français. Ann Dermatol Venereol 1995;122:289-91.
159. Lienard D. Utilité du bilan initial pour les mélanomes de stade I. Ann Dermatol Venereol 1995;122:285-8.
160. Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests [Comment in: Arch Dermatol. 2001 Oct;137(10):1361-3]. Arch Dermatol 2001;137:1343-50.
161. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3:159-65.
162. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy [Comment in: J Clin Oncol. 2003 Oct 1;21(19):3706; author reply 3706-7; Comment in: J Clin Oncol. 2003 Oct 1;21(19):3707; author reply 3707-8]. J Clin Oncol 2003;21:520-9.
163. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients - monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002;87:151-7.
164. Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D, Goggins W. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004;140:67-70.
165. Heaston DK, Putman CE, Rodan BA, Nicholson E, Ravin CE, Korobkin M, et al. Solitary pulmonary metastases in high-risk melanoma patients: a prospective comparison of conventional and computed tomography. AJR Am J Roentgenol 1983;141:169-74.
166. Kostrubiak I, Whitley NO, Aisner J, Goose P, DeLuca RR, Didolkar MS, et al. The use of computed body tomography in malignant melanoma. JAMA 1988;259:2896-7.
167. Buzaid AC, Sandler AB, Mani S, Curtis AM, Poo WJ, Bolognia JL, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993;11:638-43.
168. Iscoe NA, et al. Predictive value of staging. Investigations in patients with clinical stage I malignant melanoma. Plast and Reconst Surg 1984;233-7.
169. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997;4:252-8.
170. Johnson TM, Fader DJ, Chang AE, Yahanda A, Smith JW, Hamlet KR, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997;4:396-402.
171. Davidoff A, Uubert F, Menu Y, et al. The liver, bilary system, pancreas and spleen. In: Vanels D, Strak, DD, eds. Imaging strategies in oncology. Londres, Dunitz: 1993;223-226.
172. Colman LK, Porter BA, Redmond J, III, Olson DO, Stimac GK, Dunning DM, et al. Early diagnosis of spinal metastases by CT and MR studies. J Comput Assist Tomogr 1988;12:423-6.
173. Bragg DG. The lung, pleura and chest wall. In : Vanels D, Strak, DD, eds. Imaging strategies in incology. Londres, Dunitz: 1993;121-144.
174. Roth JA, Eilber FR, Bennett LR, Morton DL. Radionuclide photoscanning. Usefulness in preoperative evaluation of melanoma patients. Arch Surg 1975;110:1211-2.
175. Thomas JH, Panoussopoulous D, Liesmann GE, Jewell WR, Preston DF. Scintiscans in the evaluation of patients with malignant melanomas. Surg Gynecol Obstet 1979;149:574-6.
176. Evans R, et al. Radionuclides scans not indicated for clinical stage I melanoma. Surg Gynecol Obstet 1980;150:5332-4.
177. Au FC, Maier WP, Malmud LS, Goldman LI, Clark WH, Jr. Preoperative nuclear scans in patients with melanoma. Cancer 1984;53: 2095-7.
178. Zartman GM, Thomas MR, Robinson WA. Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol 1987;35:163-4.
179. Ardizzoni A, Grimaldi A, Repetto L, Bruzzone M, Sertoli MR, Rosso R. Stage I-II melanoma: the value of metastatic work-up. Oncology 1987;44:87-9.
180. Khansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 1989;124:847-9.
181. Jonsson PE, Hafstrom L, Hugander A, Cederquist E. Value of liver scintigraphy in pretreatment staging and in follow-up of patients with malignant melanoma. J Surg Oncol 1985;29:22-5.
182. Serrone L, Solivetti FM, Thorel MF, Eibenschutz L, Donati P, Catricala C. High frequency ultrasound in the preoperative staging of primary melanoma: a statistical analysis. Melanoma Res 2002;12:287-90.
183. Partsch B, Binder M, Puspok-Schwarz M, Wolff K, Pehamberger H. Limitations of high frequency ultrasound in determining the invasiveness of cutaneous malignant melanoma. Melanoma Res 1996;6:395-8.
184. Lassau N, Koscielny S, Avril MF, Margulis A, Duvillard P, De Baere T, et al. Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of melanomas. AJR 2002; American Journal of Roentgenology. 178:1547-51.
185. Bafounta ML, Beauchet A, Chagnon S, Saiag P. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis [Comment in: Lancet Oncol. 2005 Jan;6(1):2; discussion 3]. Lancet Oncol 2004;5:673-80.
186. Binder M, Kittler H, Steiner A, Dorffner R, Wolff K, Pehamberger H. Lymph node sonography versus palpation for detecting recurrent disease in patients with malignant melanoma. Eur J Cancer 1997;33:1805-8.
187. Blum A, Schlagenhauff B, Stroebel W, Breuninger H, Rassner G, Garbe C. Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1,288 patients. Cancer 2000;88:2534-9.
188. Brountzos EN, Panagiotou IE, Bafaloukos DI, Kelekis DA. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma. Oncol Rep 2003;10:505-10.
189. Nazarian LN, Alexander AA, Rawool NM, Kurtz AB, Maguire HC, Mastrangelo MJ. Malignant melanoma: impact of superficial US on management. Radiology 1996;199:273-7.
190. Prayer L, Winkelbauer H, Gritzmann N, Winkelbauer F, Helmer M, Pehamberger H. Sonography versus palpation in the detection of regional lymph-node metastases in patients with malignant melanoma. Eur J Cancer 1990;26:827-30.
191. Rossi CR, Seno A, Vecchiato A, Foletto M, Tregnaghi A, De Candia A, et al. The impact of ultrasound scanning in the staging and follow-up of patients with clinical stage I cutaneous melanoma. Eur J Cancer 1997;33:200-3.
192. Rossi CR, Mocellin S, Scagnet B, Foletto M, Vecchiato A, Pilati P, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol 2003;83:80-4.
193. Schmid-Wendtner MH, Paerschke G, Baumert J, Plewig G, Volkenandt M. Value of ultrasonography compared with physical examination for the detection of locoregional metastases in patients with cutaneous melanoma. Melanoma Res 2003;13:183-8.
194. Stutte H, Erbe S, Rassner G. Lymphknotensonographie in der Nachsorge des malignen Melanoms [Lymph node sonography in the after care of malignant melanoma]. Hautarzt 1989;40:344-9.
195. Voit C, Mayer T, Kron M, Schoengen A, Sterry W, Weber L, et al. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. Cancer 2001;91:2409-16.
196. Bernard, M. Intérêt de l'échographie superficielle des adénopathies pour le diagnostic des métastases ganglionnaires de mélanome [Thèse. Université de Paris V; 2002.
197. Saiag P. Recommendations for an effective follow-up strategy in melanoma patients should be tailored to the investigations performed during initial staging [Comment on: J Clin Oncol. 2003 Feb 1;21(3):520-9]. J Clin Oncol 2003;21:3706-7.
198. Voit C, Mayer T, Proebstle TM, Weber L, Kron M, Krupienski M, et al. Ultrasound-guided fine-needle aspiration cytology in the early detection of melanoma metastases. Cancer 2000;90:186-93.
199. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 1983;51:840-3.
200. Campora E, Repetto L, Giuntini P, Bertelli G, Amoroso D, Sertoli MR, et al. LDH in the follow-up of stage I malignant melanoma. Eur J Cancer Clin Oncol 1988;24:277-8.
201. Karnell R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kagedal B. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 1997;7:393-9.
202. Karnell R, Kagedal B, Lindholm C, Nilsson B, Arstrand K, Ringborg U. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res 2000;10:363-9.
203. Mohammed MQ, Abraha HD, Sherwood RA, MacRae K, Retsas S. Serum S100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol 2001;18:109-20.
204. Gogas H, Kefala G, Bafaloukos D, Frangia K, Polyzos A, Pectasides D, et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br J Cancer 2002;87:181-6.
205. Wakamatsu K, Kageshita T, Furue M, Hatta N, Kiyohara Y, Nakayama J, et al. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience. Melanoma Res 2002;12:245-53.
206. Kersey PA, Iscoe NA, Gapski JA, Osoba D, From L, DeBoer G, et al. The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 1985;72:614-7.
207. Metastatic spread of stage I melanoma of the skin. Tumori 1983;69:449-54.
208. Margenthaler JA, Johnson DY, Virgo KS, Fosko SW, Chan D, Goshima K, et al. Evaluation of patients with clinically suspected melanoma recurrence: current practice patterns of plastic surgeons. Int J Oncol 2002;21:591-6.
209. Margenthaler JA, Meier JD, Virgo KS, Johnson DY, Goshima K, Chan D, et al. Geographic variation in posttreatment surveillance intensity for patients with cutaneous melanoma. Am J Surg 2003;186:194-200.
210. Barzilai DA, Cooper KD, Neuhauser D, Rimm AA, Cooper GS. Geographic and patient variation in receipt of surveillance procedures after local excision of cutaneous melanoma. J Invest Dermatol 2004;122:246-55.
211. Virgo KS, Chan D, Handler BS, Johnson DY, Goshima K, Johnson FE. Current practice of patient follow-up after potentially curative resection of cutaneous melanoma. Plast Reconstr Surg 2000;106:590-7.
212. Goerz G, Schulte-Beerbuhl R, Roder K, Schoppe WD, Munchhoff C, Jungblut RM. Malignes Melanom. Welche Untersuchungen sind fur Staging und Verlaufskontrollen sinnvoll? [Malignant melanoma: which examinations are useful in staging and follow-up?]. Dtsch Med Wochenschr 1986;111:1230-3.
213. Brandt SE, Welvaart K, Hermans J. Is long-term follow-up justified after excision of a thin melanoma (less than or equal to 1.5 mm)? A retrospective analysis of 206 patients. J Surg Oncol 1990;43:157-60.
214. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993;5:174-80.
215. Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995;191:199-203.
216. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999;86:2252-8.
217. e ed. Paris: Masson, 1999.
218. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-7.
219. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-9.
220. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-5.
221. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000;89:1019-25.
222. Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 1998;187:191-7.
223. Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 2000;42:606-11.
224. Boni R, Boni RA, Steinert H, Burg G, Buck A, Marincek B, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556-62.
225. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
226. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of (18)F- fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001;91:1530-42.
227. Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000;44:153-67.
228. Jenicke L, Klutmann S, Bohuslavizki KH, Neuber K, Altenhoff J, Wedler J, et al. Conventional staging and (18)F-FDG-PET staging of malignant melanoma. Radiology and Oncology 2001;35:95-103-50.
229. Mercier GA, Alavi A, Fraker DL. FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results. Clin Nucl Med 2001;26:832-6.
230. Loffler M, Weckesser M, Franzius C, Nashan D, Schober O. Malignant melanoma and (18)F-FDG-PET: Should the whole body scan include the legs? Nuklearmedizin 2003;42:167-72.
231. Wagner JD, Schauwecker D, Davidson D, Coleman JJ, Saxman S, Hutchins G, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508-15.
232. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-42.
233. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-4.
234. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma [see comments]. Arch Dermatol 1995;131:1394-8.
235. Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: (18)FDG PET imaging versus sentinel node detection. Oncologist 2002;7:271-8.
236. Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003;29:662-4.
237. Mijnhout GS, Hoekstra OS, van Lingen A, van Diest PJ, Ader HJ, Lammertsma AA, et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol 2003;56:283-6.
238. Mijnhout GS, Comans EF, I, Raijmakers P, Hoekstra OS, Teule G-JJ, Boers M, et al. Reproducibility and clinical value of (18)F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Nucl Med Commun 2002;23:475-81.
239. Holder WDJ, White RLJ, Zuger JH, Easton EJJ, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764-9.
240. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and followup of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients [see comments]. Cancer 1998;82:1664-71.
241. Steinert HC, Huch BR, Buck A, Boni R, Berthold T, Marincek B, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-9.
242. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997;64:181-9.
243. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770-6.